-
1.发明授权
公开(公告)号：EP0786083B1
公开(公告)日：2000-08-09
申请号：EP95935420.0
申请日：1995-09-30
发明人： BANG, Holger , BRUNE, Kay , WENDEL, Albrecht , TIEGS, Gesa
CPC分类号： C12Q1/533 , G01N33/50 , Y10T436/106664
摘要： A process is disclosed for detecting states of shock and for following the therapy of state of shock patients. For that purpose, the cyclophiline concentration in the patient's blood is determined by (a) enzymological methods, (b) immunological detection methods by means of specific antibodies, (c) peptidic chemical methods, (d) radiochemical methods, and is used to evaluate the severity of the state of shock. Also disclosed is the use of medicaments, biological active substances and physicochemical methods that reduce active cyclophiline concentration in the blood of state of shock patients for the therapy of states of shock, in particular septic shock, post-operative shock and toxic shock.
-
公开(公告)号：EP0641200B1
公开(公告)日：1998-12-02
申请号：EP93912719.7
申请日：1993-05-19
发明人： GEISSLINGER, Gerd , BRUNE, Kay , BAUER, Kurt , HUBER, Anton, S.
CPC分类号： A61K31/19 , A61K9/2009
摘要： A process is disclosed for preparing a composition of 2-arylpropionic acid derivates which can be more easily shaped into tablets and which contains known additives or excipients. The arylpropionic acid is mixed with a calcium compound and is pressed into tablets after the remaining additives and/or excipients have been admixed. Also disclosed are thus prepared pharmaceutical compositions.
摘要翻译： 公开了一种制备2-芳基丙酸衍生物的组合物的方法，该组合物可以更容易地成型为片剂并含有已知的添加剂或赋形剂。 芳基丙酸与钙化合物混合并在剩余的添加剂和/或赋形剂混合后压制成片剂。 因此也公开了药物组合物。
-
3.发明授权VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-KAPPA B THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN 有权作者R-芳基丙酸为药物的制造，用于人和动物疾病的治疗，其通过NF-κB的THERAPEUTIC影响来抑制活化用途
公开(公告)号：EP1154766B1
公开(公告)日：2007-01-03
申请号：EP00904922.2
申请日：2000-01-17
发明人： GEISSLINGER, Gerd , BRUNE, Kay
IPC分类号： A61K31/192 , A61P29/00
CPC分类号： A61K31/192
-
4.发明公开VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-KAPPA B THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN 有权作者R-芳基丙酸为药物的制造，用于人和动物疾病的治疗，其通过NF-κB的THERAPEUTIC影响来抑制活化用途
公开(公告)号：EP1154766A2
公开(公告)日：2001-11-21
申请号：EP00904922.2
申请日：2000-01-17
发明人： GEISSLINGER, Gerd , BRUNE, Kay
IPC分类号： A61K31/192 , A61P29/00
CPC分类号： A61K31/192
摘要： The invention relates to the use of R-antimers of aryl propionic acids or aryl propionic acid derivatives for producing medicaments that inhibit the NF-λB activation cascade. Said medicaments are therefore suitable for treating diseases that can be positively influenced by the inhibition of NF-λB formation from a therapeutic standpoint.
-
5.发明授权
公开(公告)号：EP0607128B2
公开(公告)日：2007-02-21
申请号：EP91914752.0
申请日：1991-08-19
发明人： GEISSLINGER, Gerd , BRUNE, Kay
-
6.发明授权
公开(公告)号：EP0607128B1
公开(公告)日：1997-09-17
申请号：EP91914752.0
申请日：1991-08-19
发明人： GEISSLINGER, Gerd , BRUNE, Kay
摘要： Described are drugs for the treatment of painful and/or inflammatory conditions with flurbiprofen, the previously separated enantiomers of flurbiprofen being combined in the ratio 99.5-0.5 % to 0.5-99.5 % and processed with the usual pharmaceutical vehicles and additives to give drugs. For pain, or chronic conditions in which pain is a dominant factor, the mixture of enantiomers contains 50-99.5 %, preferably 60-95 %, of R(-)-fluorbiprofen and for inflammations, or chronic conditions in which inflammation is a dominant factor, the mixture contains 50-99.5 %, preferably 60-95 %, of S(+)-flurbiprofen.
-
7.发明公开VERFAHREH ZUR DIAGNOSTISCHEN BEURTEILUNG UND VERLAUFSKONTROLLE SOWIE ARZNEIMITTEL ZUR THERAPIE VON SCHOCKZUSTÄNDEN BEIM MENSCHEN 失效VERFAHREH用于诊断评估和开发控制及药物用于治疗休克状态在人类
公开(公告)号：EP0786083A1
公开(公告)日：1997-07-30
申请号：EP95935420.0
申请日：1995-09-30
发明人： BANG, Holger , BRUNE, Kay , WENDEL, Albrecht , TIEGS, Gesa
CPC分类号： C12Q1/533 , G01N33/50 , Y10T436/106664
摘要： A process is disclosed for detecting states of shock and for following the therapy of state of shock patients. For that purpose, the cyclophiline concentration in the patient's blood is determined by (a) enzymological methods, (b) immunological detection methods by means of specific antibodies, (c) peptidic chemical methods, (d) radiochemical methods, and is used to evaluate the severity of the state of shock. Also disclosed is the use of medicaments, biological active substances and physicochemical methods that reduce active cyclophiline concentration in the blood of state of shock patients for the therapy of states of shock, in particular septic shock, post-operative shock and toxic shock.
-
8.发明公开
公开(公告)号：EP0607128A1
公开(公告)日：1994-07-27
申请号：EP91914752.0
申请日：1991-08-19
发明人： GEISSLINGER, Gerd , BRUNE, Kay
摘要： Un médicament est utile pour traiter des maladies douloureuses et/ou inflammatoires avec du flurbiprofène. Les énantiomères de flurbiprofène séparés au préalable sont combinés dans un rapport compris entre 99,5:0,5 % et 0,5:99,5 % et transformés en médicaments avec des excipients et adjuvants pharmaceutiques usuels. Le mélange d'énantiomères contient entre 50 et 99,5 %, de préférence entre 60 et 95 % de R(-)-flurbiprofène, dans le cas du traitement de douleurs ou d'états pathologiques chroniques dans lesquels prédominent les phénomènes douloureux, et entre 50 et 99,5 %, de préférence entre 60 et 95 % de S(+)-flurbiprofène, dans le cas du traitement d'inflammations et d'états pathologiques chroniques dans lesquels prédominent les phénomènes inflammatoires.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
